Mixed mitral valve disease

Article written and reviewed by Dr Luca Moretti

Mixed mitral valve disease is the coexistence of stenosis and regurgitation in the same mitral valve. The orifice does not open sufficiently during diastole and the leaflets fail to achieve competent coaptation during systole: blood therefore encounters an obstacle while entering the left ventricle and, on the next beat, part of it returns to the atrium. This interaction creates a specific hemodynamic burden that cannot be reconstructed by mechanically adding two echocardiographic grades.

Mixed disease must be distinguished from multiple valve disease, in which different valves are involved. It must also be distinguished, both clinically and conceptually, from isolated mitral stenosis and isolated mitral regurgitation. In the combined form, regurgitation increases diastolic flow through the narrowed orifice, whereas stenosis limits filling and may attenuate the ventricular dilatation expected from regurgitation.

Diagnostic difficulty is greatest when both components are moderate. The gradient may be high relative to valve area, the ventricle may fail to dilate despite important regurgitation, and indices validated for an isolated lesion may become discordant. Proper assessment measures opening and coaptation separately, then integrates heart rate, flow, atrial pressure, pulmonary circulation, rhythm and biventricular consequences. If findings remain incongruent, multimodality imaging and exercise physiology take precedence over arbitrary selection of a single number.

Specific evidence is limited: many stenosis trials exclude more than mild regurgitation, and many regurgitation studies exclude significant stenosis. The 2025 ESC/EACTS guidelines, however, explicitly recognize the mixed mitral phenotype and recommend a decision based on overall damage even when valve area does not reach the traditional threshold for clinically significant stenosis. Management therefore requires a Heart Valve Centre before atrial fibrillation, pulmonary hypertension and right-sided failure become irreversible.

Definition, etiology and anatomy of the mixed lesion

The classic cause is rheumatic heart disease. Inflammation and scarring fuse the commissures, thicken the leaflet margins, shorten and fuse the chordae, and deform the papillary muscles. Fusion reduces opening, whereas retraction and loss of leaflet surface prevent closure: the same anatomical process therefore causes both stenosis and regurgitation. The balance changes over time and after commissurotomy, because opening may improve at the cost of greater regurgitation or refusion may restore obstruction.

Globally, the rheumatic form remains predominant and may present at a young age, with pregnancy and infections unmasking a previously tolerated load. In high-income countries, the degenerative phenotype due to mitral annular calcification has become more common. Posterior calcium extends toward the leaflet bases and subvalvular apparatus, narrows the inflow tunnel and reduces excursion and coaptation. It does not produce the typical rheumatic commissural fusion and requires different anatomical and therapeutic criteria.

Severe MAC is associated with age, kidney disease, abnormalities of mineral metabolism, hypertension and previous radiation exposure; it is also a marker of vascular and myocardial comorbidity. The gradient may result from both anatomical narrowing and high flow, tachycardia and reduced atrioventricular compliance. Regurgitation results from posterior leaflet restriction, poor apposition, calcium extending into leaflet tissue or superimposed dilatation. Thus, not every patient with extensive calcium has the same physiology.

A surgical repair may leave a small ring and residual regurgitation; over time, pannus, retraction or recurrence of the lesion can produce mixed dysfunction. After TEER, the double orifice reduces valve area while residual or recurrent regurgitation preserves the systolic component. This iatrogenic form follows the same hemodynamic logic, but it must be distinguished from native disease and from prosthetic degeneration because anatomy, normal reference values and reintervention options differ.

Less common causes include mediastinal radiation therapy, serotonergic or ergot-derived drugs, lupus and antiphospholipid antibody syndrome. Congenital abnormalities with dysplastic leaflets, parachute mitral valve, double orifice or hammock mitral valve may combine obstruction and incompetence. Endocarditis and chordal rupture superimposed on an already stenotic valve cause acute deterioration; in that setting, tolerance depends on atrial compliance rather than on the slow natural history of the chronic lesion.

Morphologic description should establish whether fused commissures, leaflet retraction, chordal disease, annular calcification or a previous device predominates. “Mixed” is not an etiologic explanation and does not automatically imply severity. Mild stenosis with severe regurgitation follows the dominant physiology of regurgitation; a very small orifice with mild regurgitation behaves as stenosis. The specific mixed phenotype is the one in which neither component can be ignored without misunderstanding symptoms and risk.

The balance between stenosis and regurgitation does not remain constant over time. Rheumatic progression simultaneously reduces valve area and coaptation surface, whereas calcification may extend asymmetrically and alter the gradient or regurgitation first; heart rate and flow, by contrast, immediately change the functional component. The atrium, pulmonary circulation and right ventricle record cumulative exposure, so an echocardiogram that appears similar years later may accompany genuine deterioration signaled by new atrial fibrillation, higher pulmonary pressure or increasing diuretic requirements.

The exact prevalence is unknown because registries and studies use different definitions. In a contemporary European registry, mixed mitral disease represented a small proportion of patients with severe left-sided valve disease, but selection excluded many moderate combinations. Rheumatic surgical cohorts and operative series for severe MAC, by contrast, include a substantial proportion of mixed phenotypes. These populations are not interchangeable and do not support a single global estimate.

Integrated pathophysiology and clinical manifestations

Stenosis creates a diastolic atrioventricular gradient and limits forward output; regurgitation returns part of systolic volume to the atrium and produces a v wave. During the following diastole, that regurgitant volume, added to pulmonary venous return, must cross the narrowed orifice. This creates an inefficient recirculation: total transmitral flow may be high while systemic output remains normal or low, and the gradient reflects both components.

In mixed mitral valve disease, the left atrium is exposed simultaneously to pressure and volume overload. Stenosis impedes atrial emptying during diastole, regurgitation fills it during systole, and reduced compliance amplifies the pressure rise even with modest volume increments. Dilatation favors atrial fibrillation, which abolishes atrial contraction, makes diastole irregular and shorter, and increases stasis; a simple transition to a high ventricular rate can therefore turn a compensated state into pulmonary edema without any sudden anatomical change.

The left ventricle does not follow the model of isolated regurgitation. Regurgitation tends to increase preload and chamber size, but stenosis limits filling; a non-dilated chamber therefore does not exclude substantial systolic regurgitation. Ejection fraction measures the proportion ejected toward both the aorta and atrium, not effective forward output alone. Apparently preserved function may coexist with low output, while rheumatic fibrosis, ischemia, hypertension or radiation injury may contribute to dysfunction that is not fully reversible.

Elevated left atrial pressure is initially transmitted to the pulmonary circulation as postcapillary hypertension, but chronic exposure induces vasoconstriction and remodeling with increased pulmonary vascular resistance. The right ventricle initially hypertrophies, then dilates and may develop secondary tricuspid regurgitation. In advanced stages, reduced output may even lower the mitral gradient and make the valve appear less severe precisely when cardiopulmonary damage is more extensive.

Exercise concentrates these interactions. Tachycardia shortens diastolic filling time, increased cardiac output and regurgitant volume raise flow through the orifice, and the gradient and pulmonary pressure may rise disproportionately. A patient with moderate resting measurements may therefore develop flow-related functional stenosis during activity. Conversely, anemia, fever, pregnancy or hyperthyroidism may raise the gradient even at rest and must be recognized before attributing it entirely to anatomy.

Initial manifestations are mainly exertional dyspnea, reduced functional capacity and fatigue. As atrial pressure rises, orthopnea, paroxysmal dyspnea, hemoptysis or pulmonary edema may occur, while palpitations suggest atrial fibrillation; low output and pulmonary hypertension promote weakness, presyncope and, later, systemic venous congestion. An embolic event or detection of an atrial thrombus may be the first manifestation even when respiratory symptoms remain modest.

On auscultation, an accentuated first heart sound and opening snap, a diastolic rumble and an apical holosystolic murmur radiating to the axilla may coexist. Fibrosis and calcium reduce mobility and soften the sounds; a rumble may also result from the increased flow caused by regurgitation. Murmur intensity does not measure the relative weight of the lesions: tight stenosis limits regurgitant volume, whereas rapid equalization of atrial and ventricular pressures may make a severe jet less conspicuous.

Natural history is marked by new symptoms, atrial fibrillation, thromboembolism, pulmonary hypertension and right-sided dysfunction more than by valve area alone. Each step reduces the likelihood of fully normalizing hemodynamics and functional capacity after intervention. The therapeutic window precedes refractory congestion and fixed pulmonary vascular remodeling; waiting until one component independently reaches an extreme threshold may be inappropriate when combined consequences are already evident.

Multiparametric imaging and hemodynamic pitfalls

Transthoracic echocardiography is the first-line examination and must answer three separate questions: what anatomy causes the two defects, how important each component is, and what overall damage they have produced. Two- and three-dimensional images, continuous- and pulsed-wave Doppler, color Doppler, atrial and ventricular volumes, pulmonary pressure and right ventricular function are obtained. Rhythm, heart rate, blood pressure, hemoglobin and volume status accompany the measurements because they condition interpretation.

In rheumatic disease, direct planimetry of the orifice in short axis is the preferred anatomical method when the imaging plane crosses the leaflet tips. Three-dimensional imaging allows alignment with the true orifice and reduces oblique sectioning. Calcification, dropout, respiration and subvalvular fusion may prevent reliable tracing; in MAC, the opening is often tunnel-shaped, nonplanar and remote from the leaflet edges, so a single planimetric area may not represent effective resistance.

A mitral valve area of 1.5 cm² or less identifies clinically significant stenosis, but in mixed disease valve area and gradient are frequently discordant. The pressure half-time formula is not automatically unusable; however, recent rheumatic data show that increasing regurgitation may cause it to underestimate valve area compared with planimetry and thus overestimate obstruction. Atrial and ventricular compliance, relaxation, aortic regurgitation, tachycardia and abrupt changes after commissurotomy add further error; the method does not quantify the global burden and should not be used in isolation.

With significant mitral regurgitation, the continuity equation based on left ventricular outflow tract stroke volume cannot be applied as though the circuit were closed. Forward aortic flow is lower than the volume crossing the mitral valve during diastole, so the formula tends to underestimate valve area; the invasive Gorlin formula also becomes problematic if the flow used does not correctly include the regurgitant component. Agreement between two methods that share the same erroneous assumption does not constitute validation.

The mean transmitral gradient is measured by tracing the complete continuous-wave Doppler envelope and reporting heart rate and rhythm. Regurgitation increases diastolic volume and may create a discordantly high gradient despite valve area above 1.5 cm². This is not merely a false positive: it expresses the combined burden experienced by the atrium and pulmonary circulation. Tachycardia, pregnancy and high-output states may produce the same effect, whereas low output and right-sided dysfunction may reduce the gradient in end-stage disease.

The mitral Doppler velocity index, the ratio of transmitral VTI to left ventricular outflow tract VTI, increases with both obstruction and regurgitant recirculation. A value above 2.5 identifies significant dysfunction in prosthetic valves and has been proposed as a global marker in native mixed disease, but it is not a universally validated threshold for intervention. It should be interpreted together with gradient, valve area, atrial volume and pulmonary pressure, without transferring prosthetic criteria uncritically to the native valve.

The regurgitant component requires integration of morphology, vena contracta, PISA, continuous-wave Doppler density and contour, pulmonary venous flow and remodeling. Standard severe-regurgitation reference values - vena contracta at least 7 mm, EROA at least 40 mm² and regurgitant volume at least 60 mL in primary MR - retain their meaning, but stenosis may limit volume and dilatation. Atrial fibrillation and high atrial pressure alter pulmonary venous flow; an eccentric jet may appear small, and multiple jets make any single measurement less robust.

PISA quantifies the regurgitant orifice when flow convergence is hemispheric and systolic flow is well defined. A rheumatic orifice may be irregular, multiple or dynamic; the convergence angle and duration of regurgitation must be considered. The volumetric Doppler method, subtracting aortic stroke volume from mitral inflow volume, is conceptually appropriate for regurgitation, but errors in diameter, nonuniform flow profile and atrial fibrillation propagate through the calculation. The same measurements should not then be reused to calculate stenotic valve area by continuity.

Left atrial size, pulmonary pressure and the right heart integrate duration and clinical relevance. Left atrial volume index may be very high, but age and atrial fibrillation contribute; an apparently normal pulmonary pressure does not exclude a major exercise-induced rise. Left ventricular volumes and function do not follow thresholds for isolated MR: absence of dilatation may be due to stenosis, and ejection fraction may overestimate useful forward output.

Three-dimensional transesophageal echocardiography defines commissures, scallops, chordae, calcium distribution and the mechanism of regurgitation, excludes atrial thrombus and assesses repairability. It is essential before complex surgery and transcatheter procedures, but sedation and altered loading conditions may reduce heart rate, gradient and regurgitation. The intraprocedural report should be compared with the outpatient study and should not downgrade disease on the basis of artificially favorable hemodynamics.

Cardiac magnetic resonance provides reproducible volumes and function and quantifies regurgitation as the difference between ventricular stroke volume and forward aortic flow. Cine imaging and, in experienced centers, 4D flow can assess opening and diastolic flow; arrhythmia and small plane-selection errors remain limitations. CT describes MAC circumference and depth, the aortomitral angle and the risk of neo-LVOT obstruction for TMVR. Unlike aortic valve calcium, the mitral calcium score is not a validated surrogate for valve area or gradient.

In patients with symptoms not explained by the resting study, exercise echocardiography documents functional capacity, gradient and pulmonary pressure at the flow level that provokes symptoms. Biomarkers and invasive pressure measurement at rest or during exercise are reasonable when causality remains ambiguous. If catheterization is used, simultaneous left atrial and ventricular pressures are more accurate than an improperly timed wedge pressure; cardiac output and the Gorlin formula must be interpreted recognizing that regurgitation violates equality of transvalvular and systemic flows.

Staging, surveillance and indications for intervention

Staging begins with the predominant component but must end with an assessment of the integrated burden. Severe stenosis with mild regurgitation, or conversely severe regurgitation with only modestly reduced area, is managed mainly according to the dominant lesion while accounting for interactions. A moderate-moderate combination instead requires integration of symptoms, gradient at the documented heart rate, exercise capacity, atrial dimensions, atrial fibrillation, pulmonary pressure and ventricular response. Calling the overall disease severe does not mean declaring both components severe.

According to the 2025 ESC/EACTS guidelines, when mitral valve area is 1.5 cm² or less, recommendations for clinically significant stenosis apply. More than mild regurgitation, however, changes the treatment modality because it is a contraindication to percutaneous commissurotomy. Symptoms, embolic risk, pulmonary pressure, anatomy and the need for other procedures therefore direct management toward surgery rather than a balloon procedure that could worsen loss of coaptation.

When valve area is greater than 1.5 cm² but moderate regurgitation coexists, replacement may be considered on the basis of symptoms, anatomical characteristics, transmitral gradient and signs of damage such as atrial enlargement, atrial fibrillation or pulmonary hypertension. This recommendation does not provide a single cutoff and does not authorize automatic intervention in every double moderate lesion. It requires confirmation that the mixed valve burden, rather than lung disease, ischemia or cardiomyopathy, explains the clinical picture.

In a study of 82 patients with rheumatic disease, valve area no greater than 1.5 cm² and at least moderate regurgitation, 45.1% experienced death, valve replacement, heart-failure hospitalization or stroke. A mean gradient of 6 mmHg or more was the only independent echocardiographic predictor, with a hazard ratio of 3.69. This finding supports the prognostic value of the overall gradient, but it comes from a small selected cohort and does not turn 6 mmHg into a universal surgical threshold.

In patients who report being asymptomatic, exercise testing, real-life activity and biomarker trends may reveal limitation masked by adaptation. In symptomatic patients with mild resting findings, an exercise-induced rise in gradient or pulmonary pressure strengthens causal attribution; the threshold must be interpreted with flow and heart rate. New atrial fibrillation, embolism, pulmonary hypertension or right-sided deterioration accelerates discussion even without a striking change in valve area.

Follow-up uses studies from the same laboratory and comparable hemodynamic conditions. Intervals depend on valve area, regurgitation, gradient, symptoms and damage: an at least moderate combination generally requires annual assessment or closer follow-up when approaching intervention, without imposing an identical schedule on every patient. Rhythm, heart rate, exercise capacity, functional class, diuretic dose, pulmonary pressure, atrial size and biventricular function are recorded; any clinical change always brings review forward.

Diuretics relieve congestion, whereas rate control prolongs diastole in atrial fibrillation and may reduce the gradient. Heart-failure therapy treats the myocardial component, but no drug separates fused commissures or recreates coaptation surface. In rheumatic disease, secondary prophylaxis is used when indicated; fever, anemia, thyroid disease and pregnancy are managed because they increase flow and may precipitate symptoms.

Thromboembolic prevention depends on phenotype rather than on the mere presence of mixed mitral valve disease. In moderate or severe rheumatic stenosis with atrial fibrillation, a vitamin K antagonist is used and DOACs are not a substitute; anticoagulation is also indicated after embolism or in the presence of left atrial thrombus and may be considered with dense spontaneous echo contrast or marked atrial enlargement. Regurgitation alone or MAC alone, without atrial fibrillation, thrombus or another indication, does not justify chronic anticoagulant therapy.

Surgical and transcatheter strategy, follow-up and prognosis

The plan is defined by a mitral Heart Team including a clinical cardiologist, imaging specialist, cardiac surgeon, interventional cardiologist and heart-failure and rhythm specialists. Beyond operative risk, it evaluates etiology, repairability, calcium, coronary arteries, tricuspid valve, pulmonary pressure, right ventricular function, life expectancy and preferences. The goal is to abolish obstruction without leaving regurgitation and to restore coaptation without creating an excessively small orifice, a more complex balance than in an isolated lesion.

Percutaneous mitral commissurotomy is effective in rheumatic stenosis with fused commissures and no more than mild regurgitation. In significant mixed disease, commissural splitting may tear a leaflet or unmask already precarious coaptation; for this reason, more than mild MR is a contraindication. Previous balloon valvuloplasty with recurrent stenosis and regurgitation requires renewed anatomical assessment: repeating the procedure without evaluating the jet mechanism risks acute regurgitation and urgent surgery.

Surgical repair is possible in selected rheumatic patients when there is sufficient tissue, calcium is limited and the subvalvular apparatus remains reconstructable. Commissurotomy, chordal mobilization, resection of fused chordae, enlargement patches and annuloplasty must be balanced to obtain both adequate opening and durable coaptation: an undersized ring creates stenosis, whereas overly aggressive commissurotomy increases regurgitation. Intraoperative echocardiography therefore verifies valve area, gradient under plausible heart-rate and flow conditions, and residual regurgitation.

In advanced rheumatic fibrosis or calcific destruction, mitral valve replacement is often more reproducible. Preserving posterior chordae and, when possible, anterior chordae maintains ventricular geometry and function. A mechanical or bioprosthetic valve is selected according to age, anticoagulation, pregnancy, adherence and lifetime strategy. Concomitant surgery addresses atrial thrombus, atrial fibrillation ablation, left atrial appendage closure, coronary disease and the tricuspid valve when indications are met.

Extensive MAC increases the risk of atrioventricular disruption, circumflex injury, embolization, leak and mismatch. Surgical techniques involving decalcification and reconstruction or implantation that accommodates the calcium require substantial expertise; none is universally superior. Age and comorbidities may account for part of the prognosis even after technically successful valve treatment, so expected benefit must be distinguished from the mere feasibility of implanting a prosthesis.

TEER reduces regurgitation by approximating the leaflets but divides the orifice and increases the gradient. Clinically significant stenosis, a small valve area or an already elevated gradient therefore generally make the procedure unsuitable for native mixed disease. It may have an exceptional role when regurgitation clearly predominates and valve area is large, with quantitative prediction of the residual gradient; no dedicated trials support systematic use in combined stenosis and regurgitation.

Transcatheter replacement can treat both components simultaneously in patients with severe MAC and prohibitive surgical risk. CT must predict anchoring, embolization, leak, left ventricular outflow tract obstruction and neo-LVOT; preventive strategies targeting the anterior leaflet or septum are sometimes needed. In the global valve-in-MAC registry, one-year mortality was 53.7%, despite functional improvement among survivors. This finding mandates rigorous selection and does not support presenting TMVR as a routine equivalent to surgery.

After any intervention, a baseline study is obtained documenting gradient, valve area, residual regurgitation, chamber volumes, pulmonary pressure and biventricular function. The gradient is reported with heart rate and hemoglobin because tachycardia, anemia, mismatch, a small ring, thrombosis and degeneration have different meanings. After repair or TEER, the combination of residual MR and an elevated gradient recreates a mixed physiology; judging success only by jet reduction may therefore overestimate the result.

A favorable prognosis includes greater functional capacity, freedom from heart failure and embolic events, regression of pressures and atrial and right-heart remodeling, not merely a mobile prosthesis. Persistent atrial fibrillation, pulmonary vascular disease, right ventricular dysfunction and ventricular fibrosis may limit recovery. The scarcity of specific prospective studies requires transparency: decisions combine guidelines, observational evidence and individual physiology, avoiding both waiting until damage is irreversible and intervening on the basis of a single flow-dependent gradient.